Eli Lilly Details Debt Structure in 2023 10-K Filing

TL;DR

**Eli Lilly's 10-K shows a complex debt portfolio with notes maturing from 2025 to 2049, indicating long-term financial planning.**

AI Summary

Eli Lilly & Co. filed its 10-K on February 21, 2024, for the fiscal year ending December 31, 2023. The filing details various financial instruments, including notes due in 2025, 2026, 2030, 2031, 2033, 2036, 2043, and 2049, with interest rates ranging from 0.5000% to 6.77%. The company's Central Index Key is 0000059478, and its business is classified under Pharmaceutical Preparations.

Why It Matters

Understanding Eli Lilly's debt structure and financial obligations provides insight into its capital management and future financial flexibility, impacting its ability to invest in R&D and growth initiatives.

Risk Assessment

Risk Level: medium — The presence of various long-term notes with different maturities and interest rates introduces interest rate risk and refinancing risk, though it also diversifies debt obligations.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
• 2024-02-21 — Filing Date (The date the 10-K was officially filed.)
• 0000059478 — Central Index Key (CIK) (Unique identifier for Eli Lilly & Co. with the SEC.)
• 132 — Public Document Count (Number of documents included in the filing.)
• 2834 — Standard Industrial Classification (SIC) (Industry code for Pharmaceutical Preparations.)

Key Players & Entities

• ELI LILLY & Co (company) — Filer of the 10-K
• 0000059478 (company) — Central Index Key (CIK) for Eli Lilly & Co
• 20231231 (date) — Conformed Period of Report
• 20240221 (date) — Filed As Of Date
• LILLY CORPORATE CTR (company) — Business Address Street 1
• INDIANAPOLIS (company) — Business Address City
• IN (company) — State of Incorporation and Business Address State
• 46285 (company) — Business Address Zip
• 3172762000 (company) — Business Phone Number
• A718NotesDueJune12025Member (dollar_amount) — Specific debt instrument

FAQ

From the Filing

0000059478-24-000065.txt : 20240221 0000059478-24-000065.hdr.sgml : 20240221 20240221114437 ACCESSION NUMBER: 0000059478-24-000065 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 132 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 24657434 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 10-K 1 lly-20231231.htm 10-K lly-20231231 true false FALSE 2023 FY 0000059478 http://fasb.org/us-gaap/2023#RestructuringSettlementAndImpairmentProvisions http://fasb.org/us-gaap/2023#RestructuringSettlementAndImpairmentProvisions http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent P1Y P3Y http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent 248 0000059478 2023-01-01 2023-12-31 0000059478 us-gaap:CommonClassAMember 2023-01-01 2023-12-31 0000059478 lly:A718NotesDueJune12025Member 2023-01-01 2023-12-31 0000059478 lly:A1.625NotesDueJune22026Member 2023-01-01 2023-12-31 0000059478 lly:A2.125NotesDueJune32030Member 2023-01-01 2023-12-31 0000059478 lly:A625Notesdue2031Member 2023-01-01 2023-12-31 0000059478 lly:A.5000EuroDenominatedNotesDue2033Member 2023-01-01 2023-12-31 0000059478 lly:A6.77NotesDueJanuary12036Member 2023-01-01 2023-12-31 0000059478 lly:A1625BritishPoundDenominatedNotesDue2043Member 2023-01-01 2023-12-31 0000059478 lly:A1.700Notesdue2049Member 2023-01-01 2023-12-31 0000059478 lly:A1.125EuroDenominatedNotesDue2051Member 2023-01-01 2023-12-31 0000059478 lly:A1.375EuroDenominatedNotesDue2061Member 2023-01-01 2023-12-31 0000059478 2023-06-30 iso4217:USD 0000059478 2024-02-16 xbrli:shares 0000059478 2022-01-01 2022-12-31 0000059478 2021-01-01 2021-12-31 iso4217:USD xbrli:shares 0000059478 2023-12-31 0000059478 2022-12-31 0000059478 us-gaap:CommonStockMember 2020-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000059478 us-gaap:RetainedEarningsMember 2020-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2020-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000059478 us-gaap:TreasuryStockCommonMember 2020-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2020-12-31 0000059478 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000059478 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000059478 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000059478 us-gaap:CommonStockMember 2021-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000059478 us-gaap:RetainedEarningsMember 2021-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2021-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000059478 us-gaap:TreasuryStockCommonMember 2021-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2021-12-31 0000059478 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000059478 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000059478 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000059478 us